NOVO.B.DK

249.45

+0.79%↑

GMAB.DK

1,717

-0.12%↓

HLUNB.DK

37.7

+0.16%↑

AMBUB.DK

70.75

-1.53%↓

ZEAL.DK

297.7

+5.98%↑

NOVO.B.DK

249.45

+0.79%↑

GMAB.DK

1,717

-0.12%↓

HLUNB.DK

37.7

+0.16%↑

AMBUB.DK

70.75

-1.53%↓

ZEAL.DK

297.7

+5.98%↑

NOVO.B.DK

249.45

+0.79%↑

GMAB.DK

1,717

-0.12%↓

HLUNB.DK

37.7

+0.16%↑

AMBUB.DK

70.75

-1.53%↓

ZEAL.DK

297.7

+5.98%↑

NOVO.B.DK

249.45

+0.79%↑

GMAB.DK

1,717

-0.12%↓

HLUNB.DK

37.7

+0.16%↑

AMBUB.DK

70.75

-1.53%↓

ZEAL.DK

297.7

+5.98%↑

NOVO.B.DK

249.45

+0.79%↑

GMAB.DK

1,717

-0.12%↓

HLUNB.DK

37.7

+0.16%↑

AMBUB.DK

70.75

-1.53%↓

ZEAL.DK

297.7

+5.98%↑

Search

Coloplast A-S (Class B)

Suletud

458.4 1.55

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

449

Max

458.5

Põhinäitajad

By Trading Economics

Sissetulek

522M

1.4B

Müük

83M

7B

P/E

Sektori keskmine

25.56

57.833

Aktsiakasum

6.32

Dividenditootlus

5.07

Kasumimarginaal

19.835

Töötajad

16,983

EBITDA

309M

2.3B

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+11.86% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

5.07%

2.47%

Järgmine tulemuste avaldamine

12. mai 2026

Järgmine dividendimakse kuupäev

20. mai 2026

Järgmine aktsia dividendi kuupäev (ex-date)

18. mai 2026

Turustatistika

By TradingEconomics

Turukapital

-17B

102B

Eelmine avamishind

456.85

Eelmine sulgemishind

458.4

Coloplast A-S (Class B) Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. märts 2026, 22:42 UTC

Tulu

Prudential PLC 2025 Adjusted Operating Profit Rises

17. märts 2026, 21:40 UTC

Tulu

Alimentation Couche-Tard Records Higher Profit, Revenue in 3Q

17. märts 2026, 23:56 UTC

Market Talk

BHP's Next CEO Likely to Build On Existing Strategic Direction -- Market Talk

17. märts 2026, 23:46 UTC

Market Talk

Nikkei May Rise After Recent Selloffs -- Market Talk

17. märts 2026, 23:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. märts 2026, 23:42 UTC

Market Talk

RBA's Return to Policy Tightening Will Work -- Market Talk

17. märts 2026, 23:38 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustments Before FOMC Decision -- Market Talk

17. märts 2026, 23:24 UTC

Market Talk

Global Energy Roundup: Market Talk

17. märts 2026, 23:24 UTC

Market Talk

New Woodside CEO Seen as Low-Risk Appointment -- Market Talk

17. märts 2026, 22:22 UTC

Market Talk

BHP Hands Reins to Growth-Focused Executive -- Market Talk

17. märts 2026, 22:20 UTC

Tulu

Prudential PLC 2025 New Business Profit $2.78B Vs. $2.46B >2378.HK

17. märts 2026, 22:20 UTC

Tulu

Prudential PLC 2025 Adj Operating Profit $3.31B Vs. $3.13B >2378.HK

17. märts 2026, 22:07 UTC

Tulu

Nvidia Says It Is Restarting Production of AI Chips for Sale in China -- WSJ

17. märts 2026, 22:05 UTC

Tulu

ZTO Express (Cayman): Frank Zhen Wei to Resign From Board

17. märts 2026, 22:04 UTC

Tulu

ZTO Express (Cayman): Board Approves Repurchase of Up to $1.5B of Shares Over Next 24 Months >ZTO

17. märts 2026, 22:03 UTC

Tulu

ZTO Express (Cayman) Raises Semiannual Dividend to 39c Vs. 30c >ZTO

17. märts 2026, 22:01 UTC

Tulu

ZTO Express (Cayman) 4Q Adj EPS 47c >ZTO

17. märts 2026, 22:01 UTC

Tulu

ZTO Express (Cayman) 4Q Rev $2.08B >ZTO

17. märts 2026, 22:01 UTC

Tulu

ZTO Express (Cayman) 4Q EPS 47c >ZTO

17. märts 2026, 21:26 UTC

Tulu

Oklo Stock Wavers After Earnings, but the Nuclear Start-Up Has Good News -- Barrons.com

17. märts 2026, 21:09 UTC

Tulu

Couche-Tard: 12 Company-Operated Stores Acquired During 3Q

17. märts 2026, 21:08 UTC

Tulu

Couche-Tard 3Q Consolidated Same-Store Merchandise Revenue Up 2% >ATD.T

17. märts 2026, 21:08 UTC

Tulu

Couche-Tard 3Q Adj EPS 81c >ATD.T

17. märts 2026, 21:07 UTC

Tulu

Couche-Tard 3Q EPS 82c >ATD.T

17. märts 2026, 21:06 UTC

Tulu

Couche-Tard 3Q Rev $21.8B >ATD.T

17. märts 2026, 21:05 UTC

Tulu

Couche-Tard 3Q Adj EPS 81c >ATD.T

17. märts 2026, 21:05 UTC

Tulu

Couche-Tard 3Q Rev $21.8B >ATD.T

17. märts 2026, 21:05 UTC

Tulu

Couche-Tard 3Q EPS 82c >ATD.T

17. märts 2026, 21:05 UTC

Tulu

Couche-Tard 3Q Net $757.2M >ATD.T

17. märts 2026, 20:50 UTC

Market Talk
Uudisväärsed sündmused

Energy & Utilities Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Coloplast A-S (Class B) Prognoos

Hinnasiht

By TipRanks

11.86% tõus

12 kuu keskmine prognoos

Keskmine 901.38 DKK  11.86%

Kõrge 1,056 DKK

Madal 720 DKK

Põhineb 8 Wall Streeti analüütiku instrumendi Coloplast A-S (Class B) 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

8 ratings

2

Osta

4

Hoia

2

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat